CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
Lanabecestat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02540668
NCT02540668Phase 1Completed
CompareCT.gov

Effect of LY3314814 on the Pharmacokinetics of Warfarin in Healthy Subjects

AstraZeneca·interventional·Posted Sep 4, 2015·Updated Nov 4, 2019

In Brief

A Phase 1 clinical trial evaluating Lanabecestat and Warfarin for Healthy. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat by measuring international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. Information about any side effects that may occur will also be collected. The study will last about 5 weeks from the first dose to follow-up for each participant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsEli Lilly and Company

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 4, 2015
Enrollment StartSep 30, 2015
Primary CompletionJan 31, 2016
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 10.8 years ago

Interventions

Lanabecestatdrug

Administered orally

Warfarindrug

Administered orally